Donghai Securities released a research report on April 24 stating that Baicheng Pharmaceutical (301096.SZ) was given a purchase rating. The main reasons for the rating include: 1) continued high growth in performance; 2) abundant orders and staff expansion; 3) commissioned research and development: rapid expansion of pre-clinical R&D and clinical business; 4) transformation of self-research results: reserves fully support rapid development; 5) CDMO: accelerated volume under synergetic effects. (Mainichi Keizai Shimbun)
东海证券4月24日发布研报称，给予百诚医药（301096.SZ）买入评级。评级理由主要包括：1）业绩保持高增长；2）订单充沛，人员扩张；3）受托研发：临床前研发和临床业务均快速扩张；4）自研成果转化：储备充分支撑高速发展；5）CDMO：协同效应下加速放量。（每日经济新闻）
Donghai Securities released a research report on April 24 stating that Baicheng Pharmaceutical (301096.SZ) was given a purchase rating. The main reasons for the rating include: 1) continued high growth in performance; 2) abundant orders and staff expansio
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.